HR Execs on the Move

Health Supply US

www.healthsupplyus.com

 
Health Supply US provides America’s leading health care facilities and first responder networks and governments with Personal Protective Equipment (PPE), Sanitizers, and COVID Testing Kits among other devices and supplies. We service government at all ...
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
KC Pelle
Chief Supply Chain Officer Profile

Similar Companies

Intellect Neurosciences

Intellect Neurosciences Inc. is a New York, NY-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

4 dry skin natural products

4 dry skin natural products is a Nashville, KY-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Madrigal Pharmaceuticals

Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need. The Company has advanced its lead candidate, resmetirom, also known as MGL-3196, a first-in-class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) β-selective agonist, through Phase 2 clinical trials in NASH. Primary and key secondary endpoints were achieved including reduction of liver fat on a sensitive non-invasive imaging test, lowering of multiple atherogenic lipids including LDL-cholesterol and triglycerides, and resolution of NASH on liver biopsy. Based on evidence of broad activity and a favorable safety profile, Madrigal has initiated a Phase 3 clinical study in NASH patients with advanced liver fibrosis, MAESTRO-NASH, in which the primary endpoint after one year of dosing is resolution of NASH and key secondary endpoints include LDL-cholesterol lowering and reduction in liver fibrosis. Clinical benefit in reducing progression to more advanced liver disease, including cirrhosis, is a long-term goal of this trial. A second Phase 3 clinical study, MAESTRO-NAFLD-1, has also been initiated. This 52-week non-invasive study in a broader segment of NASH patients will provide additional safety information to support the NASH indication and will include key efficacy endpoints: LDL-cholesterol lowering, triglyceride lowering, reduction of liver fat as determined by MRI-PDFF, as well as reduction of elevated liver enzymes and reduction in fibrosis biomarkers. This is a non-biopsy study in people with NASH, as documented using non-invasive techniques or historical liver biopsy.

Mississippi Sports Medicine

Mississippis first full-service orthopaedic speciality practice. #AnyAge #AnySport #AnyInjury Just come here; weve got you covered.

QRxPharma Limited

QRxPharma Limited is a Bedminster, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.